These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38686708)

  • 1. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Berglund E; Chen Y
    Clin Pharmacol Ther; 2024 Sep; 116(3):563-576. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modeling in obesity: applications and challenges.
    Yang R; Ding Q; Ding J; Zhu L; Pei Q
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):805-816. PubMed ID: 39101366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.
    Johnson TN; Small BG; Berglund EG; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
    Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
    Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 8. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically Based Pharmacokinetic modelling of drugs in pregnancy: A mini-review on availability and limitations.
    Berezowska M; Sharma P; Pilla Reddy V; Coppola P
    Fundam Clin Pharmacol; 2024 Jun; 38(3):402-409. PubMed ID: 37968879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
    Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
    Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
    Tsakalozou E; Mohamed MF; Polak S; Heimbach T
    AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.
    Sychterz C; Galetin A; Taskar KS
    Biopharm Drug Dispos; 2021 Apr; 42(4):160-177. PubMed ID: 33759451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
    Min JS; Bae SK
    Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson TN; Ke AB
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration.
    Sun Z; Zhao N; Zhao X; Wang Z; Liu Z; Cui Y
    Eur J Pharm Sci; 2024 Sep; 200():106838. PubMed ID: 38960205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation.
    Franchetti Y; Nolin TD
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S36-S51. PubMed ID: 33205428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.